Please login to the form below

Not currently logged in
Email:
Password:

Ignyta

This page shows the latest Ignyta news and features for those working in and with pharma, biotech and healthcare.

Roche’s rival to Bayer’s Vitrakvi gets speedy FDA review

Roche’s rival to Bayer’s Vitrakvi gets speedy FDA review

Roche acquired rights to entrectinib when it bought Ignyta for $1.7bn just over a year ago, having licensed rights to the drug in a $1.55bn deal a few weeks

Latest news

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Pharma deals in March 2015 Pharma deals in March 2015

    Two days' later Teva acquired four oncology development programmes (the most advanced in phase I/II) from Ignyta for $42m.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....